HAI Book 2025 - Flipbook - Page 61
Concordance between visual and quantitative
amyloid PET and CSF biomarkers in the ADNIDOD cohort
Calibration of multi-site raters for prospective
visual read of amyloid PET scans acquired
across the ADRC Consortium for Clarity in ADRD
Research Through Imaging (CLARiTI)
Evaluating the effect of APOE genotype in realworld clinical settings: results from the IDEASANGI study
Brain connectivity drives tau distribution while
regional vulnerability drives tau load in
Alzheimer9s disease
Synergistic effects of peripheral inflammation
and neuroinflammation on amyloid, vascular,
and neurodegeneration markers across the
Alzheimer9s disease spectrum
Impact of amyloid removal on cerebral volume
changes with Gantenerumab
Astrocyte reactivity explains tau-related effects
on hippocampal dysfunction and longitudinal
atrophy in preclinical Alzheimer9s disease
Plasma phosphorylated tau 217 and longitudinal
trajectories of A´, tau, and cognition in
cognitively unimpaired older adults
Detection of TDP-43 from plasma-derived
astrocyte extracellular vesicles for identification
of LATE
Short sleep duration is associated with higher
subsequent plasma p-tau217 in aging
Impacts of testing language and rates of amyloid
positivity among underrepresented groups in
the A4 Study
Lower locus coeruleus metabolism is associated
with greater year-to-year intraindividual
cognitive variability in older individuals with
elevated levels of Alzheimer9s disease pathology
Long-term cognitive and biomarker trajectories
of cognitively unimpaired individuals with
elevated plasma ptau-217
A large public release of PIB PET and MRI from
the Mayo Clinic Study of Aging
Harmonizing visual readings of Flortaucipir and
MK-6240 using head-to-head data
Twin-mapping techniques in clinical trials: a
proof-of-concept application to the InternetBased Conversational Engagement Clinical Trial
(I-CONECT)
Effects of amyloid and tau status on multiplex
plasma CNS and inflammatory proteins in a
normal aging cohort
Tau imaging thresholds within NIA-AA multilevel
tau staging as predictors of tau accumulation
and cognitive decline in non-demented
individuals
HAI2025 - 61
Agathe Vrillon, University of California San
Francisco, San Francisco, CA, US
David Soleimani-Meigooni, Department of
Neurology, Memory and Aging Center, Weill
Institute for Neurosciences, University of
California, San Francisco, CA, US
Stefania Pezzoli, Memory and Aging Center,
Department of Neurology, University of
California, San Francisco, San Francisco, CA, US
Yu Xiao, Department of Clinical Sciences Malmö,
SciLifeLab, Lund University, Lund, SE
Laura Alejandra Ramirez Tirado, Department of
Epidemiology, University of Pittsburgh,
Pittsburgh, PA, US
Matteo Tonietto, Research and Early
Development (pRED), Hoffmann-La Roche,
Basel, CH
Noah Schweitzer, Department of
Bioengineering, University of Pittsburgh,
Pittsburgh, PA, US
Hyun-Sik Yang, Brigham and Women's Hospital,
Boston, MA, US
Robert Rissman, University of Southern
California, Neuroscience Translational Research
Division, Alzheimer's Therapeutic Research
Institute, SAN DIEGO, CA, US
Joseph Winer, Department of Neurology and
Neurological Sciences, Stanford University,
Stanford, CA, US
Isha Sai, Department of Neurology and
Neurological Sciences, Stanford University,
Stanford, CA, US
Emma E Wiklund, The Athinoula A. Martinos
Center for Biomedical Imaging, Department of
Radiology, Massachusetts General Hospital,
Harvard Medical School, Boston, MA, US
Jesús Silva-Rodríguez, Reina Sofia Alzheimer
Centre, CIEN Foundation, ISCIII, Madrid, ES
Christopher Schwarz, Mayo Clinic, Rochester,
MN, US
Emma Ruppert, University of Pittsburgh,
Department of Psychiatry, Pittsburgh, PA, US
Chao-Yi Wu, Neurology, Massachusetts General
Hospital (MGH), Harvard Medical School,
Charlestown, MA, US
Karly Cody, Department of Neurology and
Neurological Sciences, Stanford University,
Stanford, CA, US
Alexandra Gogola, Department of Radiology,
University of Pittsburgh School of Medicine,
Pittsburgh, PA, US
